anti-SARS-CoV-2 inactivated convalescent plasma

Anti-SARS-CoV-2 inactivated convalescent plasma is a blood product derived from individuals who have recovered from COVID-19. The therapy involves collecting plasma containing high titers of neutralizing antibodies against SARS-CoV-2 and then subjecting it to pathogen reduction or inactivation processes (such as photochemical treatment with amotosalen and ultraviolet A light) to ensure safety by reducing the risk of transfusion-transmitted infections. The primary mechanism is passive immunization—transferring ready-made antibodies to patients with active infection or at risk of severe disease, thereby providing immediate but temporary immune protection. This approach has been used especially for hospitalized patients with severe or life-threatening COVID-19, particularly when other treatments are limited[1][2][5]. Clinical studies suggest that early administration and higher antibody titers may improve outcomes[3][5].

Other names

COVID-19 convalescent plasmaCOVID19 convalescent plasmaCOVID 19 convalescent plasmaSARS-CoV-2 convalescent plasmaSARS-CoV2 convalescent plasmaSARS-CoV 2 convalescent plasmainactivated COVID-19 convalescent plasma